22
Participants
Start Date
October 13, 2025
Primary Completion Date
June 3, 2027
Study Completion Date
June 3, 2027
426c.Mod.Core-C4b
self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
3M-052-AF
3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
Aluminum hydroxide suspension (Alum)
Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.
Placebo and Diluent
Tris-NaCl buffer.
Soweto HVTN CRS, Soweto
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Fred Hutchinson Cancer Center
OTHER
Access to Advanced Health Institute
UNKNOWN
HIV Vaccine Trials Network
NETWORK